

What is claimed is:

1. A method to protect a mammal from a disease characterized by eosinophilia associated with an inflammatory response, said method comprising administering a heat shock protein to a mammal having said disease.

2. The method of Claim 1, wherein said disease is associated with increased production of a cytokine selected from the group consisting of interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-13 (IL-13) and interleukin-15 (IL-15).

3. The method of Claim 1, wherein said disease is selected from the group consisting of allergic airway diseases, hyper-eosinophilic syndrome, helminthic parasitic infection, allergic rhinitis, allergic conjunctivitis, dermatitis, eczema, contact dermatitis, and food allergy.

4. The method of Claim 1, wherein said disease is a respiratory disease characterized by eosinophilic airway inflammation and airway hyperresponsiveness.

5. The method of Claim 4, wherein said respiratory disease is selected from the group consisting of allergic asthma, intrinsic asthma, allergic bronchopulmonary aspergillosis, eosinophilic pneumonia, allergic bronchitis, bronchiectasis, occupational asthma, reactive airway disease

syndrome, interstitial lung disease, hyper-eosinophilic syndrome, and parasitic lung disease.

6. The method of Claim 1, wherein said disease is associated with sensitization to an allergen.

7. The method of Claim 1, wherein said disease is allergic asthma.

8. The method of Claim 1, wherein said heat shock protein is selected from the group consisting of an HSP-60 family heat shock protein, an HSP-70 family heat shock protein, an HSP-90 family heat shock protein and an HSP-27 family heat shock protein.

9. The method of Claim 1, wherein said heat shock protein is selected from the group consisting of an HSP-60 family heat shock protein, an HSP-70 family heat shock protein and an HSP-27 family heat shock protein.

10. The method of Claim 1, wherein said heat shock protein is selected from the group consisting of an HSP-90 family heat shock protein and an HSP-27 family heat shock protein.

11. The method of Claim 1, wherein said heat shock protein is selected from the group consisting of a bacterial heat shock protein and a mammalian heat shock protein.

12. The method of Claim 1, wherein said heat shock protein is a mycobacterial heat shock protein.

13. The method of Claim 1, wherein said heat shock protein is a mycobacterial heat shock protein-65 (HSP-65).

14. The method of Claim 1, wherein said heat shock protein is administered by at least one route selected from the group consisting of oral, nasal, topical, inhaled, transdermal, rectal and parenteral routes.

15. The method of Claim 1, wherein said heat shock protein is administered by a route selected from the group consisting of inhaled and nasal routes.

16. The method of Claim 1, wherein said heat shock protein reduces eosinophilia in said mammal.

17. The method of Claim 1, wherein said heat shock protein reduces eosinophil blood counts in said mammal to between about 0 and about 300 cells/mm³.

18. The method of Claim 1, wherein said heat shock protein reduces eosinophil blood counts in said mammal to between about 0 and about 100 cells/mm³.

19. The method of Claim 1, wherein said heat shock protein reduces eosinophil blood counts in said mammal to between about 0% and about 3% of total white blood cells in said mammal.

20. The method of Claim 1, wherein said heat shock protein induces interferon- γ (IFN- γ) production by T lymphocytes in said mammal.

21. The method of Claim 1, wherein said heat shock protein suppresses interleukin-4 (IL-4) and interleukin-5 (IL-5) production by T lymphocytes in said mammal.

22. The method of Claim 1, wherein said heat shock protein decreases airway methacholine responsiveness in said mammal.

23. The method of Claim 1, wherein said heat shock protein reduces airflow limitation in said mammal such that an FEV₁/FVC value of said mammal is at least about 80%.

24. The method of Claim 1, wherein said heat shock protein results in an improvement in a mammal's PC_{20methacholine}FEV₁ value such that the PC_{20methacholine}FEV₁ value obtained before administration of said heat shock protein when the mammal is provoked with a first concentration of methacholine is the same as the PC_{20methacholine}FEV₁ value obtained after administration of said heat shock protein when the mammal is provoked with double the amount of the first concentration of methacholine.

25. The method of Claim 24, wherein said first concentration of methacholine is between about 0.01 mg/ml and about 8 mg/ml.

26. The method of Claim 1, wherein said heat shock protein improves a mammal's FEV₁ by between about 5% and about 100% of said mammal's predicted FEV₁.

27. The method of Claim 1, wherein said heat shock protein reduces airflow limitation in said mammal such that an R_L value of said mammal is reduced by at least about 20%.

28. The method of Claim 1, wherein said heat shock protein is administered in an amount between about 0.1 microgram x kilogram⁻¹ and about 10 milligram x kilogram⁻¹ body weight of a mammal.

29. The method of Claim 1, wherein said heat shock protein is administered in an amount between about 1 microgram x kilogram⁻¹ and about 1 milligram x kilogram⁻¹ body weight of a mammal.

30. The method of Claim 1, wherein said heat shock protein is administered in an amount between about 0.1 milligram x kilogram⁻¹ and about 5 milligram x kilogram⁻¹ body weight of a mammal, if said heat shock protein is delivered by aerosol.

31. The method of Claim 1, wherein said heat shock protein is administered in an amount between about 0.1 microgram x kilogram⁻¹ and about 10 microgram x kilogram⁻¹ body weight of a mammal, if said heat shock protein is delivered parenterally.

32. The method of Claim 1, wherein said heat shock protein is administered in a pharmaceutically acceptable excipient.

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813

34. A method for prescribing treatment for airway hyperresponsiveness or airflow limitation associated with a disease involving an inflammatory response, comprising:

- 5
- a. administering to a mammal a heat shock protein;
 - b. measuring a change in lung function in response to a provoking agent in said mammal to determine if said heat shock protein modulates airway hyperresponsiveness or airflow limitation; and,
 - c. prescribing a pharmacological therapy comprising administration of said heat shock protein to said mammal effective to reduce inflammation based upon said changes in lung function.
- 10
- 15

35. The method of Claim 34, wherein said disease is characterized by airway eosinophilia.

36. The method of Claim 34, wherein said provoking agent is selected from the group consisting of a direct and an indirect stimuli.

37. The method of Claim 34, wherein said provoking agent is selected from the group consisting of an allergen, methacholine, a histamine, a leukotriene, saline, hyperventilation, exercise, sulfur dioxide, adenosine,

5 propranolol, cold air, an antigen, bradykinin, acetylcholine,
a prostaglandin, ozone, environmental air pollutants and
mixtures thereof.

38. The method of Claim 34, wherein said step of
measuring comprises measuring a value selected from the group
consisting of FEV₁, FEV₁/FVC, PC_{20methacholine} FEV₁, post-enhanced h
(Penh), conductance, dynamic compliance, lung resistance (R_L),
5 airway pressure time index (APTI), and peak flow.

39. A method to protect a mammal from a disease characterized by airway hyperresponsiveness associated with an inflammatory response, said method comprising administering a heat shock protein to a mammal having said disease.

40. A method to protect a mammal from an inflammatory disease characterized by a Th2-type immune response, said method comprising administering a heat shock protein to a mammal having said disease.

41. A formulation for protecting a mammal from developing a disease characterized by eosinophilia associated with an inflammatory response, comprising a heat shock protein and an anti-inflammatory agent.

42. The formulation of Claim 41, wherein said anti-inflammatory agent is selected from the group consisting of an antigen, an allergen, a hapten, proinflammatory cytokine antagonists, proinflammatory cytokine receptor antagonists, anti-CD23, anti-IgE, leukotriene synthesis inhibitors, leukotriene receptor antagonists, glucocorticosteroids, steroid chemical derivatives, anti-cyclooxygenase agents, anti-cholinergic agents, beta-adrenergic agonists, methylxanthines, anti-histamines, cromones, zyleuton, anti-CD4 reagents, anti-IL-5 reagents, surfactants, anti-thromboxane reagents, anti-serotonin reagents, ketotiphen, cytoxin, cyclosporin, methotrexate, macrolide antibiotics, heparin, low molecular weight heparin, and mixtures thereof.

43. The formulation of Claim 41, wherein said formulation comprises a pharmaceutically acceptable excipient.

44. The formulation of Claim 41, wherein said formulation comprises a pharmaceutically acceptable excipient selected from the group consisting of biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion

devices, liposomes, lipospheres, and transdermal delivery systems.

45. The method of Claim 41, wherein said heat shock protein is selected from the group consisting of an HSP-60 family heat shock protein, an HSP-70 family heat shock protein, an HSP-90 family heat shock protein and an HSP-27 family heat shock protein.

46. The method of Claim 41, wherein said heat shock protein is a mycobacterial heat shock protein.

47. The method of Claim 41, wherein said heat shock protein is a mycobacterial heat shock protein-65 (HSP-65).

48. A method to protect a mammal from a disease identified by a characteristic selected from the group consisting of eosinophilia, airway hyperresponsiveness and a Th2-type immune response, said characteristic being associated with an inflammatory response, said method comprising administering a nucleic acid molecule encoding a heat shock protein to a mammal having said disease.

49. The method of Claim 48, wherein said nucleic acid molecule is operatively linked to a transcription control sequence.

50. The method of Claim 48, wherein said nucleic acid molecule is administered with a pharmaceutically acceptable excipient selected from the group consisting of an aqueous physiologically balanced solution, an artificial lipid-containing substrate, a natural lipid-containing substrate, an oil, an ester, a glycol, a virus, a metal particle and a cationic molecule.

51. The method of Claim 48, wherein said pharmaceutically acceptable excipient is selected from the group consisting of liposomes, micelles, cells and cellular membranes.

52. The method of Claim 48, wherein said nucleic acid molecule is administered by a mode selected from the group consisting of intradermal injection, intramuscular injection,

intravenous injection, subcutaneous injection, and ex vivo
administration.

5